Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT02477696 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02477696
- Sponsor
- Acerta Pharma BV
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-07-28
- Primary completion
- 2020-09-15
- Enrollment
- 533
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.